The six main possible clinical applications of HPV DNA testing are: (i) triage of women with equivocal or low-grade cytological abnormalities; (ii) follow-up of women with abnormal screening results who are negative at colposcopy/biopsy; (iii) prediction of the therapeutic outcome after treatment of cervical intraepithelial neoplasia (CIN); (iv) primary screening for HPV DNA testing, alone or HPV screening or HPV/cytology co-testing every 5 years for women age d 30-65 years old [2]. However, decreases in HR HPV positivity rates due to HPV vaccination and additional research have Use. High-risk HPV test is used for types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, without differentiation of the individual type. If the initial high-risk test is positive, then the residual specimen will be tested for HPV types 16 and 18,45; type 18 cannot be differentiated from type 45.
A total of 5880 women with normal cytology and hr-HPV infection accepted colposcopic biopsy were enrolled in this study. 4332 women underwent HPV genotyping test and 1548 women were hr-HPV DNA positive by HC2 hr-HPV DNA test (Fig. 1). The median age was 39 years (26–81), and the average age was 39.29 ± 9.72 years.

Testing for human papillomavirus (HPV) HPV testing is part of cervical screening. There's no blood test for HPV. During cervical screening, a small sample of cells is taken from the cervix and tested for HPV. Screening is offered to all women and people with a cervix aged 25 to 64. It helps protect them against cervical cancer.

Key Points. Question Is menstrual blood high-risk human papillomavirus (hrHPV) capture sequencing a feasible and accurate approach for HPV detection?. Findings In this cohort study of 120 women with hrHPV, menstrual blood hrHPV capture sequencing had a high concordance rate with cervical HPV testing and offered advantages in the detection of additional hrHPV genotypes and true negative samples. Since high-risk human papillomavirus (HR-HPV) is associated with almost 90% of cases of anal cancer, the objective of this study is to evaluate whether testing for HR-HPV can optimize the screening. Prospective study with patients enrolled in a screening program for anal dysplasia. Considering high-resolution anoscopy (HRA)-guided biopsy as the UCaSz.
  • c3q6hhwntw.pages.dev/755
  • c3q6hhwntw.pages.dev/249
  • c3q6hhwntw.pages.dev/38
  • c3q6hhwntw.pages.dev/381
  • c3q6hhwntw.pages.dev/978
  • c3q6hhwntw.pages.dev/641
  • c3q6hhwntw.pages.dev/975
  • c3q6hhwntw.pages.dev/409
  • c3q6hhwntw.pages.dev/29
  • c3q6hhwntw.pages.dev/837
  • c3q6hhwntw.pages.dev/748
  • c3q6hhwntw.pages.dev/274
  • c3q6hhwntw.pages.dev/892
  • c3q6hhwntw.pages.dev/476
  • c3q6hhwntw.pages.dev/302

    • hpv dna test negative means